NCCN 2021 Virtual Congress: Hematologic Malignancies
Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines
Ronald S. Go, MD, of Mayo Clinic Cancer Center, discusses the new NCCN Clinical Practice Guidelines in Oncology for the most common types of histiocytic neoplasms in adults—Erdheim-Chester disease, La...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition ...
Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, talks about whether modifications of treatment based on minimal residual disease is beneficial to patients with chroni...
Alice S. Mims, MD, on AML: Updates on Managing Newly Diagnosed Disease
Alice S. Mims, MD, of The Ohio State University Comprehensive Cancer Center, discusses the many positive changes over the past 5 years in treating patients with newly diagnosed acute myeloid leukemia ...
